Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression

Complete pathological response to neoadjuvant treatment (NAT) in breast cancer is associated with prolonged survival. Compared to other breast cancer immunophenotypes, luminal tumors are the least chemosensitive with low rates of pathological response within this molecular subtype. Thus, finding pre...

ver descrição completa

Detalhes bibliográficos
Autores: Miras, Isabel, Gil, Ana, Benavent, Marta, Castilla, María Ángeles, Vieites, Begoña, Dominguez-Cejudo, María Ángeles, Molina-Pinelo, Sonia, Alfaro, Lina, Frutos, Javier, Ruiz-Borrego, Manuel, Falcón, Alejandro, Cejuela, Mónica, Salvador-Bofill, Javier
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/387094
Acesso em linha:http://hdl.handle.net/10261/387094
https://api.elsevier.com/content/abstract/scopus_id/85213960974
Access Level:acceso abierto
Palavra-chave:Biomarker
Breast neoplasms
ki67
Neoadjuvant therapy
Pathological response
Descrição
Resumo:Complete pathological response to neoadjuvant treatment (NAT) in breast cancer is associated with prolonged survival. Compared to other breast cancer immunophenotypes, luminal tumors are the least chemosensitive with low rates of pathological response within this molecular subtype. Thus, finding predictors of response in this subset remains challenging. The emerging concept of low human epidermal growth factor receptor 2 (HER2) expression has led to a repurpose of the current prognostic system. Little is known about its correlation with response to NAT.

Registos relacionados